BioTech 365
MAY 11, 2021
Million Worldwide Recombinant DNA Technology Industry to 2027 – Impact of COVID-19 on the Market – ResearchAndMarkets.com $609.8
Roots Analysis
JANUARY 21, 2024
Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment. This trend is expected to continue in the foreseeable future.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cloudbyz
MARCH 6, 2024
Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. Biosimilars have the potential to lower healthcare costs, increase market competition, and improve patient access to biologic therapies.
Pharmaceutical Technology
FEBRUARY 15, 2023
Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.
pharmaphorum
FEBRUARY 22, 2021
But instead rivals such as BioNTech/Pfizer, AstraZeneca and Moderna have made it to market first with their vaccines. Sanofi’s shot combines the recombinant DNA technology it uses to make flue vaccines with the adjuvants GSK uses to boost the immune system with its jabs.
The Pharma Data
JULY 11, 2021
TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. Depending on regional marketing authorization, TAKHZYRO is available as a 300 mg dose in a vial or pre-filled syringe. TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity.
Expert insights. Personalized for you.
40 
Let's personalize your content